¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"amyloidosis of multiple myeloma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® multiple myeloma ÇÑ±Û ´Ù¹ß°ñ¼öÁ¾
¼³¸í   
  ´Ù¹ß¼º ¿ø¹ß¼º°ñÁ¾¾ç. ¸Ó¸®»À-°¥ºñ»À-º¹Àå»À-ôÃß»À-°ñ¹Ý µî¿¡ Àß ³ªÅ¸³ª°í, ¹°··¹°··ÇÑ Á¾±«¸¦ Çü¼ºÇϸç, »ÀÀÇ Èí¼ö°¡ ÀϾ°í, 40~60¼¼ ³²ÀÚ¿¡°Ô ¸¹ÀÌ ¹ß»ýÇÑ´Ù. °ñ¼öÁ¾ Á¾¾ç¼¼Æ÷´Â ÇüÁú¼¼Æ÷¿¡¼­ À¯·¡ÇÑ °ÍÀ̾ ÇüÁú¼¼Æ÷Á¾À̶ó°íµµ ÇÑ´Ù. °ú°Å¿¡´Â ÇüÁú¼¼Æ÷¼º°ñ¼öÁ¾ À̿ܿ¡´Â ´Ù¸¥ °ñ¼öÁ¶Ç÷¿ä¼Ò¿¡¼­ »ý±â´Â °ñ¼öÁ¾À̶ó°í »ý°¢ÇßÁö¸¸ ÇöÀç´Â ºÎÁ¤µÇ°í ÀÖ´Ù. ÇüÁú¼¼Æ÷´Â ¿ø·¡ ¸é¿ª±Û·ÎºÒ¸°À» »ý»êÇϴ ¼¼Æ÷À̸ç, ±×°ÍÀÌ Á¾¾çÈ­ÇÑ ´Ù¹ß °ñ¼öÁ¾ È¯ÀÚ¿¡¼­µµ ´ëºÎºÐ Ç÷û ¼Ó¿¡ ¸é¿ª ±Û·ÎºÒ¸°ÀÌ Áõ°¡µÈ °ÍÀ» º¼ ¼ö ÀÖ´Ù. Áõ°¡ÇÑ ±Û·ÎºÒ¸°Àº IgG³ª IgAÀΠ°æ¿ì°¡ ¸¹Áö¸¸ ´Ù¸¥ Çüµµ ÀÖ´Ù. °ñ¼öÁ¾ È¯ÀÚ ¾à 50%´Â ¿ÀÁÜ¿¡¼­ º¥½ºÁÔ½º´Ü¹éÁúÀÌ °ËÃâµÇ´Âµ¥, ÀÌ ´Ü¹éÁúÀÇ ÃàÀû¿¡ ÀÇÇØ ¿ä¼¼°üÀÌ ÆÄ±«µÇ°í, ÄáÆÏ°æÈ­°¡ ÀϾ´Ù. °ñ¼öÁ¾ È¯ÀÚ¿¡¼­´Â Ç÷û´Ü¹é ÀÌ»óÀ¸·Î °¡²û ¾Æ¹Ð·ÎÀ̵åÁõÀÌ ³ªÅ¸³­´Ù. »À X¼± ¼Ò°ßÀ¸·Î¼­´Â µµ·Á³½ º´ÅÍ, °ñÀ¶ÇØ»ó, º´Àû°ñÀýÀÌ °üÂûµÈ´Ù.
¿µ¹® amyloidosis ÇÑ±Û ¾Æ¹Ð·ÎÀ̵åÁõ
¼³¸í   
  º»·¡ »ýü¿¡´Â ¾ø´Â ´ç´Ü¹éÁúÀÇ ÀÏÁ¾À¸·Î ºñÁ¤»óÀûÀ¸·Î ¾Æ¹Ð·ÎÀ̵å´Ü¹éÀÌ Á¶Á÷À̳ª Àå±â¿¡ Ä§ÂøµÇ´Â º´. ¹ßÇöºÎÀ§°¡ Àü½Å¼ºÀΠ°æ¿ìÀÇ ¾Æ¹Ð·ÎÀ̵åÁõ(Àü½Å¼º ¾Æ¹Ð·ÎÀ̵åÁõ)¿¡´Â ¸í¹éÇÑ ¿øÀξøÀÌ ÀϾ´Â ¿ø¹ß¼º ¾Æ¹Ð·ÎµåÁõ°ú ¸¸¼ºÈ­³ó¼º ¿°ÁõÀ̳ª °áÇÙ µî ¼Ò¸ð¼º Áúȯ¿¡¼­ Ã£¾Æº¼ ¼ö Àִ ¼Ó¹ß¼º ¾Æ¹Ð·ÎÀ̵åÁõÀÌ ÀÖ´Ù. ¹ßÇöºÎÀ§°¡ ±¹¼Ò¼ºÀΠ°æ¿ìÀÇ ±¹¼Ò¼º ¾Æ¹Ð·ÎÀ̵åÁõÀ¸·Î¼­´Â ³úÀÇ ³ëÀιÝÀÌ ±× ¿¹À̸ç, Æ¯È÷ ÀԾȿ¡¼­´Â Çô³ª ÀÕ¸ö¿¡ ´ëÇÑ Ä§ÂøÀÌ ÇöÀúÇÏ°í ¿©·¯ °¡Áö ±â´ÉÀå¾Ö¸¦ ³ªÅ¸³½´Ù. Á¶Á÷ÇÐÀûÀ¸·Î´Â Ç츶Åå½Ç¸° ¿¡¿ÀÁø¿°»ö¿¡¼­´Â ¿¡¿ÀÁø¼º ¹«±¸Á¶ÀΠÀ¯¸®È­¸¦ ³ªÅ¸³»¸ç Äá°í·¹µå, Æí±¤»ó(³ì»ö) µîÀ¸·Î È®ÀÎÇÑ´Ù. ±¸Á¶ÀûÀ¸·Î´Â ¾Æ¹Ð·ÎÀ̵堼¶À¯ÀÇ ÁýÇÕÀ¸·Î ÀÌ·ç¾îÁö´Â ¿©·¯ °¡Áö ¾Æ¹Ð·ÎÀ̵å Ä§ÂøÀÌ ÀÖÀ¸¸ç ±×°Íµé¿¡ ´ëÇÑ º´ÇüÀÌ ºÐ·ùµÇ¾î ÀÖ´Ù. °¡Á·Çü, ´Ù¹ß¼º °ñ¼öÁ¾°ú ¼ö¹ÝÇϴ Çü ±×¸®°í °¡Á·¼º ÁöÁßÇØ¿­À» ¼ö¹ÝÇϴ Çü µîÀÌ ÀÖ´Ù.
¿µ¹® multiple sclerosis ÇÑ±Û ´Ù¹ß°æÈ­Áõ
¼³¸í   
  ½Å°æÃà»èÀ» µÑ·¯½Î°í Àִ ¸»ÀÌÁý(myelin sheath)ÀÇ ÆÄ±«·Î ÀÎÇÑ º´Àû»óŸ¦ ¸»ÇÔ. ÆÄ±«µÈ ¸»ÀÌÁýÀº ÈäÅ͸¦ ³²±â°Ô µÇ¾î ½Å°æÃà»èÀ» ÅëÇÑ ½Å°æÀü´ÞÀÌ Á¦´ë·Î µÇÁö ¾Ê¾Æ ¿îµ¿, °¨°¢, ÀÚÀ²½Å°æ ¸ðµÎÀÇ ½Å°æÀü´ÞÀå¾Ö°¡ ³ªÅ¸³­´Ù. ÀÌ º´Åʹ ¾îµð¼­³ª ³ªÅ¸³¯ ¼ö À־ ±× Àå¾Ö°¡ ³ªÅ¸³ª´Â ºÎÀ§¿¡ µû¶ó ¼­·Î ´Ù¸¥ Áõ»óÀ» È£¼ÒÇÑ´Ù.
¿µ¹® multiple personality ÇÑ±Û ´ÙÀμº ÀΰÝ
¼³¸í   
  Çظ®¼º Á¤½ÅÀå¾ÖÀÇ Çϳª·Î ³ªÅ¸³­´Ù. ÇÑ »ç¶÷ÀÌ ¿©·¯ »ç¶÷ÀÇ ¼º°ÝÀ» ¼ÒÀ¯Çϰí Àִ °ÍÀ¸·Î ¸¶Ä¡ ¡°Áöų¹Ú»ç¿Í ÇÏÀ̵堾¾¡±¿Í °°Àº °æ¿ìÀÌ´Ù. ¾Æ¸¶, ÇöÀç ÀÚ½ÅÀǠóÁö¿¡¼­ ¹þ¾î³ª°í ½ÍÀº ¹«ÀǽÄÀûÀΠ¿å¸Á¿¡¼­ ºñ·ÔµÇ´Â °ÍÀ¸·Î ¿©°ÜÁø´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • amyloidosis
    ¾Æ¹Ð·ÎÀ̵åÁõ
  • endocardial amyloidosis
    ½É(Àå)³»¸·¾Æ¹Ð·ÎÀ̵åÁõ
  • generalized amyloidosis
    Àü½Å¾Æ¹Ð·ÎÀ̵åÁõ
  • nodular amyloidosis
    °áÀý¾Æ¹Ð·ÎÀ̵åÁõ
  • primary amyloidosis
    ¿ø¹ß¾Æ¹Ð·ÎÀ̵åÁõ
  • systemic amyloidosis
    Àü½Å¾Æ¹Ð·ÎÀ̵åÁõ
  • senile amyloidosis
    ³ë³â¾Æ¹Ð·ÎÀ̵åÁõ
  • extramedullary myeloma
    °ñ¼ö¿Ü°ñ¼öÁ¾
  • giant cell myeloma
    °Å´ë¼¼Æ÷°ñ¼öÁ¾
  • localized myeloma
    ±¹ÇѰñ¼öÁ¾
  • myeloma
    °ñ¼öÁ¾
  • myeloma cell
    °ñ¼öÁ¾¼¼Æ÷
  • myeloma globulin
    °ñ¼öÁ¾±Û·ÎºÒ¸°
  • myeloma kidney
    °ñ¼öÁ¾ÄáÆÏ, °ñ¼öÁ¾½ÅÀå
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • amyloidosis
    ¾Æ¹Ð·ÎÀ̵åÁõ
  • myeloma
    °ñ¼öÁ¾
  • solitary myeloma
    °í¸³°ñ¼öÁ¾
  • multiple birth
    ´Ù»ê, ´ÙÅÂÃâ»ê
  • plural multiple birth
    ´Ù»ê, ´ÙÅÂÃâ»ê
  • multiple
    ´Ù¹ß-, ¿©·¯-, ¹µ-, ´Ù-
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
  • multiple sclerosis
    ´Ù¹ß°æÈ­Áõ
  • multiple causation theory
    Áúº´¹ß»ý´Ù¿äÀμ³
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • amyloidosis
    ¾Æ¹Ð·ÎÀ̵åÁõ
  • endocardial amyloidosis
    ½ÉÀå³»¸·¾Æ¹Ð·ÎÀ̵åÁõ
  • generalized amyloidosis
    Àü½Å¾Æ¹Ð·ÎÀ̵åÁõ
  • nodular amyloidosis
    °áÀý¾Æ¹Ð·ÎÀ̵åÁõ
  • primary amyloidosis
    ¿ø¹ß¾Æ¹Ð·ÎÀ̵åÁõ
  • senile amyloidosis
    ³ëÀξƹзÎÀ̵åÁõ
  • systemic amyloidosis
    Àü½Å¾Æ¹Ð·ÎÀ̵åÁõ
  • myeloma cell
    °ñ¼öÁ¾¼¼Æ÷
  • extramedullary myeloma
    °ñ¼ö¿Ü¼º°ñ¼öÁ¾
  • giant cell myeloma
    °Å´ë¼¼Æ÷°ñ¼öÁ¾
  • myeloma globulin
    °ñ¼öÁ¾±Û·ÎºÒ¸°
  • myeloma kidney
    °ñ¼öÁ¾ÄáÆÏ
  • localized myeloma
    ±¹ÇѰñ¼öÁ¾
  • myeloma
    °ñ¼öÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • G-myeloma protein
    ¸é¿ª±Û·ÎºÒ¸° G-°ñ¼öÁ¾´Ü¹éÁú
  • giant cell myeloma
    °Å¼¼Æ÷°ñ¼öÁ¾.
  • globulin, myeloma
    °ñ¼öÁ¾±Û·ÎºÒ¸°
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷ °ñ¼öÁ¾
  • plasma cell myeloma
    ÇüÁú¼¼Æ÷°ñ¼öÁ¾(û¡òõá¬øàÍéâÐðþ)
  • Cowdens syndrome = multiple hamartoma syndrome
    ´Ù¹ß¼º °ú¿ÀÁ¾ ÁõÈıº
  • MOTSA (multiple overlapping thin-slab acquisition)
    ´ÙÁß Áߺ¹ ¼¼ÆíÆÇ ȹµæ
  • infection, multiple
    ´ÙÁß°¨¿°, º¹¼ö±Õ°¨¿°
  • infectious multiple gangrene of skin
    Àü¿°¼º ÇǺΠ´Ù¹ß¼º ±«Àú
  • personality disorder, multiple
    ´ÙÁß(Òýñì) ÀΰÝÀå¾Ö
  • personality, multiple
    ´ÙÁßÀΰÝ.
  • plural birth =multiple b.
    ´Ùźи¸(Òý÷à ÝÂØ´).
  • amyloidosis
    ¾Æ¹Ð·ÎÀ̵åÁõ, À¯ÀüºÐÁõ
  • amyloidosis
    ¾Æ¹Ð·ÎÀ̵åÁõ, À¯ÀüºÐÁõ.
  • amyloidosis
    ¾Æ¹Ð·ÎÀ̵åÁõ(¡­ñø), À¯ÀüºÐÁõ(ëºîþÝÏñø)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • multiple myeloma
    ´Ù¹ß¼º °ñ¼öÁ¾(¡­ÍéâÐðþ)
  • multiple myeloma
    ¹æ»ç ´Ù¹ß¼º °ñ¼öÁ¾(?Ë­ËàÌ¡).
  • myeloma, multiple
    °ñ¼öÁ¾, ´Ù¹ß¼º(ÒýÛ¡àõ)
  • extramedullary myeloma
    °ñ¼ö ¿Ü¼º°ñ¼öÁ¾
  • giant cell myeloma
    °Å¼¼Æ÷°ñ¼öÁ¾.
  • globulin, myeloma
    °ñ¼öÁ¾±Û·ÎºÒ¸°
  • localized myeloma
    ±¹ÇѼº°ñ¼öÁ¾
  • myeloma
    °ñ¼öÁ¾
  • myeloma
    °ñ¼öÁ¾(¡­ðþ)
  • myeloma cell
    °ñ¼öÁ¾¼¼Æ÷(¡­á¬øà).
  • myeloma globulin
    °ñ¼öÁ¾±Û·ÎºÒ¸°.
  • myeloma kidney
    °ñ¼öÁ¾½Å(Àå)(¡­ãìíô)
  • myeloma kidney
    °ñ¼öÁ¾½Å(Àå)(Ë­ËàÌ¡ËàËö).
  • myeloma nephrosis
    °ñ¼öÁ¾¼º ½ÅÁõ(¡­àõ ãìñø)
  • myeloma protein
    °ñ¼öÁ¾´Ü¹éÁú
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Multiple placenta
    ¹µÅ¹Ý
    [¿¾ ¿ë¾î] ´Ù¹ß¼ºÅ¹Ý
  • Multiple deformity
    º¹ÇÕ±âÇü
    [¿¾ ¿ë¾î] ´Ù¹ß¼º±âÇü
  • Multiple morphologic defect
    º¹ÇÕÇüŰáÇÔ
    [¿¾ ¿ë¾î] ´Ù¹ß¼ºÇüÅÂÇÐÀû°áÇÔ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • multiple budding
    ´Ù¼öÃâ¾Æ
  • multiple fission
    ´ÙºÐ¿­
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • amyloidosis
    ¾Æ¹Ð·ÎÀ̵åÁõ(ñø)
  • A myeloma protein
    °ñ¼öÁ¾´Ü¹éÁú(ÍéâÐðþÓ±ÛÜòõ) A
  • G myeloma protein
    G °ñ¼öÁ¾ ´Ü¹éÁú(ÍéâÐðþÓ±ÛÜòõ)
  • myeloma protein
    °ñ¼öÁ¾´Ü¹éÁú(ÍéâÐðþÓ±ÛÜòõ)
  • multiple alleles
    º¹´ë¸³À¯ÀüÀÚ(ÜÜÓߨ¡ë¶îîí­)
  • multiple binding
    ´ÙÁß°áÇÕ(ÒýñëÌ¿ùê)
  • multiple codon recognition
    ´Ù(Òý)ÄÚµ· ÀÎÁö(ìãò±)
  • multiple displacement mechanism
    ´Ù(Òý)´ëü(ÓÛôð) ±âÀü(Ѧï®)
  • multiple factor hypothesis
    ´ÙÀÎÀÚ¼³(Òýì×í­àã)
  • multiple gene
    ´ÙÀ¯ÀüÀÚ(Òýë¶îîí­)
  • multiple inhibition analysis
    ´ÙÁß(Òýñì)ÀúÇØ ºÐ¼®(îÁúªÝÂà°)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • multiple myeloma
    ´Ù¹ß¼º°ñ¼öÁ¾
  • amyloidosis
    ¾Æ¹Ð·ÎÀ̵åÁõ, À¯ÀüºÐÁõ
  • myeloma
    °ñ¼öÁ¾
  • MOTSA [=multiple overlapping thin-slab acquisition]
    ´ÙÁßÁߺ¹¼¼ÆíÆÇȹµæ
  • multiple
    ´Ù¹ß¼º
  • multiple cranial nerve palsy
    ´Ù¹ß¼º³ú½Å°æ¸¶ºñ
  • multiple echo
    ´ÙÁß¿¡ÄÚ
  • multiple epiphyseal dysplasia
    ´Ù¹ß¼º°ñ´ÜÀÌÇü¼ºÁõ
  • multiple excitaiton
    ´ÙÁß¿©±â
  • multiple exostoses
    ´Ù¹ß¼º¿Ü°ñÁõ
  • multiple fibroma
    ´Ù¹ß¼º¼¶À¯Á¾
  • multiple lymphomatous polyposis
    ´Ù¹ß¼º¸²ÇÁÁ¾¼º¿ëÁ¾Áõ
  • multiple overlapping thin slab acquisition [=MOTSA]
    ´ÙÁßÁߺ¹¼¼ÆíÆÇȹµæ
  • multiple polyp
    ´Ù¹ß¼ºÆú¸³
  • multiple sclerosis
    ´Ù¹ß¼º°æÈ­Áõ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
B-J protein Bence-Jones Protein
  ÀÇÀÇ; Multiple Myeloma
MM Multiple Myeloma
MM macromolecule; Maelzels metronome; major medical [insurance]; malignant melanoma; manubrium to malle...
SMM smoldering multiple myeloma
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
M.M. Multiple Myeloma
SMM Smoldering multiple myeloma
AL Amyloidosis
DRA Dialysis related amyloidosis
FAF Familial amyloidosis, Finnish type
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • multiple myeloma
    ´Ù¹ß¼º °ñ¼öÁ¾, ´Ù¹ß¼º ÇüÁú ¼¼Æ÷Á¾
    1. °ñ¼öÀÇ ¾Ç¼º ½Å»ý¹°. 2. ÇüÁú ¼¼Æ÷ Áúȯ±º Áß °¡Àå Áß¿äÇϰí ÈçÇÑ ÇüÅ·μ­ °ñ°Ý°è¿Í ¶§·Î ¿¬°ñ ºÎÀ§¿¡ ¼º¼÷ ¶Ç´Â ¹Ì¼º¼÷ ÇüÁú ¼¼Æ÷µéÀÌ ´Ù¹ß¼º Á¾±â¸¦ Çü¼ºÇÏ´Â °æ¿ìÀÌ´Ù. 3. ´Ù¹ß¼º °ñ¼öÁ¾Àº ³­Ä¡¼º ¾Ç¼º Ç÷¾× Á¾¾çÀÌ´Ù. ´Ù¸¥ Á¾¾çµé°ú ¸¶Âù°¡Áö·Î ¿øÀÎÀº ¸ð¸£¸ç ÁÖ¿ä Áõ»óÀ¸·Î´Â »ÀÀÇ ¾àÈ­, °ñÀý µîÀÌ °¡Àå ÈçÇϰí, ºóÇ÷, ½Å ºÎÀü, °¨¿° µîÀ¸·Î ³ªÅ¸³­´Ù. º´±â´Â 1, 2, 3±â·Î ³ª´©¸ç ´ë°³ 3±â¿¡ ÁÖ·Î ¹ß°ßµÇ³ª ±Ù·¡¿¡´Â °Ç°­ Áø´Ü µîÀ» ÅëÇØ Á¶±â¿¡ ¹ß°ßµÇ±âµµ ÇÑ´Ù. ´ëÁõÀûÀÎ Ä¡·á°¡ Áß¿äÇϸç Áúȯ ÀÚü¿¡ ´ëÇÑ Ç¥ÁØ Ä¡·áÀÇ ¼ºÀûÀº ¸¸Á·½º·´Áö ¾Ê´Ù. Ä¡·á¸¦ ¹ÞÁö ¾ÊÀº °æ¿ì´Â Æò±Õ ¼ö¸íÀÌ ¼ö°³¿ù¿¡ ºÒ°úÇϰí Ä¡·áÇÑ °æ¿ìÀÇ Æò±Õ ¼ö¸íÀº 3³â Á¤µµÀ̳ª 3±â¿¡¼­´Â 1³â ³»¿ÜÀÌ´Ù. 1990³â´ë¿¡ Ä¡·á ¹æ¹ýÀÌ ¹ß´ÞÇÏ¿© ÀÎÅÍÆä·Ð°ú °ñ¼ö À̽ÄÀÌ ¼Ò°³µÇ¾ú´Ù. ÀÎÅÍÆä·ÐÀº ȯÀÚÀÇ º´ÀÌ ¸¹ÀÌ °¨¼ÒÇÏ¿© Ä¡·á¸¦ Áß´ÜÇÑ °æ¿ì Àç¹ßÀ» ´ÊÃß´Â È¿°ú°¡ °ËÁõµÇ¾ú´Ù. ȯÀÚÀÇ °ñ¼ö, ȤÀº ±ÙÀÚ¿¡´Â ¸»ÃÊÇ÷¾×ÀÇ Á¶Ç÷¸ð¼¼Æ÷¸¦ À̽ÄÇÏ°í °í¿ë·®ÀÇ Ç×¾Ï Ä¡·á¸¦ ÇÏ´Â ÀÚ°¡ ÀÌ½Ä Ä¡·á´Â ÇöÀç±îÁö Æò±Õ ¼ö¸íÀÌ 5³âÀÌ »óÀ¸·Î º¸°íµÇ¾î °ú°ÅÀÇ Ä¡·á¹ý°ú´Â ¿ùµîÇÑ Çâ»óÀ» º¸¿© Ȱ¹ßÇÑ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ´Ù. ÃÖ±Ù¿¡´Â ÀÚ°¡ À̽Ŀ¡¼­µµ ¾Ï ¼¼Æ÷°¡ ¾ø´Â Á¶Ç÷¸ð¼¼Æ÷¸¸À» ÃßÃâÇÏ¿© À̽ÄÇϴ ÷´ÜÀÇ Ä¡·á¹ýÀÌ ¼Ò°³µÇ°í ÀÖ¾î ¿ÏÄ¡¸¦ ÇâÇØ ÇÑ °ÉÀ½¾¿ ÁøÇàµÇ°í ÀÖ´Ù°í º¸¿©Áø´Ù. ´Ù¹ß¼º °ñ¼öÁ¾ÀÇ Áø´ÜÀº Southwest Oncology Grou
  • multiple fission,multiple division
    ´Ù ºÐ¿­
    1°³ÀÇ ¸ð¼¼Æ÷°¡ ÀϽÃÀûÀ¸·Î ´Ù¼öÀÇ µþ ¼¼Æ÷·Î ³ª´©¾îÁö´Â ÀÏ. º¹ ºÐ¿­À̶ó°íµµ ÇÑ´Ù. ¸ðü°¡ 2°³ÀÇ µþ °³Ã¼·Î ³ª´©¾îÁö´Â 2ºÐ¿­¿¡ ´ëÇÏ¿© ÀϽÿ¡ ´Ù¼öÀÇ µþ °³Ã¼·Î ºÐ¿­ÇÏ´Â Çö»óÀ» ¸»ÇÑ´Ù. ¿ø»ýµ¿¹° Æ÷ÀÚÃæ·ùÀÇ Áõ¿ø»ý½Ä µî¿¡¼­ º¼ ¼ö ÀÖ´Ù. Áï, ÇÙ¸¸ÀÌ ºÐ¿­À» µÇÇ®ÀÌÇÏ¿© ´ÙÇÙü°¡ µÈ µÚ¿¡ ¼¼Æ÷ÁúÀÌ ÀÏÁ¦È÷ ºÐ¿­ÇÏ¿© °¢°¢ ÇÙ 1°³¾¿À» ÇÔÀ¯ÇÏ´Â µþ °³Ã¼·Î ³ª´©¾îÁø´Ù.
  • endocardial amyloidosis
    ½É³»¸· ¾Æ¹Ð·ÎÀ̵åÁõ
  • hereditary amyloidosis
    À¯Àü¼º À¯ÀüºÐÁõ
    1. À¯Àü¿¡ ÀÇÇØ ¿ø¼¶À¯¼º ´ç ´Ü¹éÀÌ ÇǺÎ, Á¡¸·, ³»ºÎ Àå±â¿¡ ħÀüµÇ´Â º´. 2. À¯ÀüÀûÀ¸·Î ½ÅüÀÇ °¢Á¾ ºÎÀ§¿¡ ¾Æ¹Ð·ÎÀ̵å
  • primary amyloidosis
    ¿ø¹ß¼º À¯ÀüºÐÁõ, ¿ø¹ß ¾Æ¹Ð·ÎÀ̵åÁõ, ¿ø¹ß¼º ¾Æ¹Ð·ÎÀ̵åÁõ
  • D-myeloma protein
    D-°ñ¼öÁ¾ ´Ü¹é
    ¸é¿ª ±Û·ÎºÎ¸°ÀÇ ÇÑ ºÎ·ùÀÎ IgD¸¦ »ý»êÇÏ´Â °ñ¼öÁ¾¿¡¼­ ¸¸µé¾îÁø ´Ü¹éÁú.
  • endothelial myeloma
    ³»ÇÇ °ñ¼öÁ¾
    µ¿ÀǾî=Ewing's sarcoma.
  • myeloma
    °ñ¼öÁ¾
    1. °ñ¼ö¿¡¼­ ¹ß°ßµÇ´Â Á¤»óÀûÀÎ Á¾·ùÀÇ ¼¼Æ÷·Î ±¸¼ºµÈ Á¾¾ç. 2. °ñ¼ö¼º ¼¼Æ÷¿¡¼­ ¹ß»ýÇÏ´Â Á¾¾ç. °ñ¼ö ¼¼Æ÷Á¾
  • myeloma globulin
    °ñ¼öÁ¾ ±Û·ÎºÒ¸°
  • affecting multiple system
    ´Ù¹ß¼º °èÅëÀ» ħ¹üÇÑ
  • discrete multiple endocrine adenomatosis syndrome
    ºÐ¸®¼º ´Ù¹ß ³»ºÐºñ ¼±Á¾ ÁõÈıº
  • multiple
    ´Ù¹ß¼º, ´Ù¼öÀÇ
  • multiple abutment
    ´Ù¼ö Áö´ëÄ¡
  • multiple allelomorph
    º¹´ë¸³ À¯ÀüÀÚ
  • multiple anchorage
    º¹ÇÕ °íÁ¤
    1Çü½Ä ÀÌ»óÀÇ ÈûÀ» °¡ÇÏ´Â ÀåÄ¡¸¦ »ç¿ëÇÏ´Â °íÁ¤.
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
amyloidosis of multiple myeloma Foci of amyloidosis in mesenchymal tissues of some persons with multiple myeloma; no direct relation between amyloid and Bence Jones protein is conclusively known.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
cancer, multiple myeloma A bone marrow cancer involving a type of white blood cell called a plasma (or myeloma) cell. The tumour cells can form a single collection (a plasmacytoma) or many tumours (multiple myeloma). Plasma cells are part of the immune system and make antibodies. Because patients have an excess of identical plasma cells, they have too much of one type of antibody. As myeloma cells increase in number, they damage and weaken the bones, causing pain and often fractures. When bones are damaged, calcium is released into the blood leading to hypercalcaemia (excess calcium in the blood) and that causes loss of appetite, nausea, thirst, fatigue, muscle weakness, restlessness, and confusion. Myeloma cells prevent the bone marrow from forming normal plasma cells and other white blood cells important to the immune system so patients may not be able to fight infections. The cancer cells can also prevent the growth of new red blood cells, causing anaemia. Excess antibody proteins and calcium may prevent the kidneys from filtering and cleaning the blood properly Cancer, non-Hodgkin's lymphoma: A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy.
(12 Dec 1998)
multiple myeloma <oncology, tumour> See myeloma cell.
(18 Nov 1997)
cancer, myeloma A bone marrow cancer involving a type of white blood cell called a plasma (or myeloma) cell. The tumour cells can form a single collection (a plasmacytoma) or many tumours (multiple myeloma). Plasma cells are part of the immune system and make antibodies. Because patients have an excess of identical plasma cells, they have too much of one type of antibody. As myeloma cells increase in number, they damage and weaken the bones, causing pain and often fractures. When bones are damaged, calcium is released into the blood leading to hypercalcaemia (too much calcium in the blood) and that causes loss of appetite, nausea, thirst, fatigue, muscle weakness, restlessness, and confusion. Myeloma cells prevent the bone marrow from forming normal plasma cells and other white blood cells important to the immune system so patients may not be able to fight infections. The cancer cells can also prevent the growth of new red blood cells, causing anaemia. Excess antibody proteins and calcium may prevent the kidneys from filtering and cleaning the blood properly.
(12 Dec 1998)
giant cell myeloma A bone tumour composed of cellular spindle-cell stroma containing scattered multinucleated giant cells resembling osteoclasts. The tumours range from benign to frankly malignant lesions. The tumour occurs most frequently in an end of a long tubular bone in young adults.
(12 Dec 1998)
plasma cell myeloma Cells resemble mature or immature plasma cells with nuclei that appear cleaved or resemble immunoblasts. The tumour cells are CD19- , CD20- , CD22- and SIg- , but are also cIg+ and CD38+. The Ig heavy and light chain genes can be translocated or deleted. These neoplasms are often disseminated BM tumours of adults and progress to multiple myeloma.
(05 Mar 2000)
myeloma <oncology, tumour> A malignant tumour composed of plasma cells of the type normally found in the bone marrow.
(18 Nov 1997)
myeloma cell <haematology, oncology> Neoplastic plasma cell. The proliferating plasma cells often replace all the others within the marrow, leading to immune deficiency and frequently there is destruction of the bone cortex. Because they are monoclonal in origin they secrete a monoclonal immunoglobulin. Bence Jones proteins are monoclonal immunoglobulin light chains overproduced by myeloma cells and excreted in the urine. Myeloma cell lines are used for producing hybridomas in raising monoclonal antibodies.
(18 Nov 1997)
myeloma protein <haematology, oncology> The immunoglobulins and Bence Jones proteins secreted by myeloma cells.
(18 Nov 1997)
endothelial myeloma A malignant primary bone tumour that arises most commonly in the first three decades of life. It is highly malignant (prone to spread) and often requires treatment with some combination of radiation therapy and chemotherapy.
(27 Sep 1997)
L-chain myeloma bence Jones myeloma
amyloidosis Deposition of amyloid. A common complication of several diseases (leprosy, tuberculosis), often associated with perturbation of the immune system, although there may be immunosuppression or enhancement.
(18 Nov 1997)
amyloidosis: bone manifestations <radiology> Joint pain without radiographic findings, osteoporosis, especially in axial skeleton, lytic lesions that destroy cortex and invade soft tissue, wrist, scaphoid and lunate lesions that may extend into the carpal tunnel, inducing the classic complaints of carpal tunnel syndrome amyloid arthropathy Differential diagnosis: pigmented villonodular synovitis, synovial chondromatosis, rheumatoid arthritis, TB
(12 Dec 1998)
amyloidosis cutis Localised cutaneous amyloidosis with pruritic brownish-red papules, most commonly on the lower legs, due to amyloid infiltration of the papillary dermis.
Synonym: amyloidosis cutis, lichen amyloidosis.
Origin: G. Leichen, lichen, a lichen-like eruption + eidos, resemblance
(05 Mar 2000)
amyloidosis: gastrointestinal manifestations <radiology> Oesophagus, loss of peristalsis, megaesophagus, stomach, small and rigid (simulate linitis plastica), effaced rugal pattern, diminished/absent peristalsis, may be localised to antrum, amyloidoma: well defined submucosal mass, small bowel, diffuse form (more common), diffuse, uniform thickening of valvulae conniventes, broadened flat undulated mucosal folds (mucosal atrophy), jejunalization of ileum, impaired motility, small bowel dilatation, localised form: multiple small deposits; associated with pseudoobstruction, colon, psudopolyps
(12 Dec 1998)
macular amyloidosis A localised form of amyloidosis cutis characterised by pruritic symmetrical brown reticulated macules, especially on the upper back; microscopically, amyloid is deposited as small subepidermal globules.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • common multiple
    °ø¹è¼ö
  • multiple
    º¹ÇÕÀÇ;´Ù¾çÇÑ;¹è¼öÀÇ;¹è¼ö;¹è¼ö·®(least common multiple ÃÖ¼Ò °ø¹è¼ö)
  • multiple choice test
    ¼±´ÙÇü Å×½ºÆ®
  • multiple cropping
    ´Ù¸ðÀÛ
  • multiple farming
    ´Ù°¢ ³ó¾÷
  • multiple shop
    ¿¬¼âÁ¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á